Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 5.00 NOK
Change Today 0.00 / 0.00%
Volume 4.3K
As of 10:25 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

pci biotech holding asa (PCIB) Snapshot

5.39 NOK
Previous Close
5.00 NOK
Day High
5.39 NOK
Day Low
4.90 NOK
52 Week High
09/8/14 - 24.92 NOK
52 Week Low
08/28/15 - 4.90 NOK
Market Cap
Average Volume 10 Days
-3.17 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for PCI BIOTECH HOLDING ASA (PCIB)

Related News

No related news articles were found.

pci biotech holding asa (PCIB) Related Businessweek News

No Related Businessweek News Found

pci biotech holding asa (PCIB) Details

PCI Biotech Holding ASA, an oncology-focused company, develops therapeutic products based on its proprietary photochemical internalization (PCI) technology. Its PCI technology induces triggered endosomal release, which enhances the therapeutic potential of various modalities, such as small molecules, ADCs, and siRNA. The company’s clinical study programs include phase II study of Amphinex based PCI with bleomycin to treat head and neck cancer; phase I/II study of Amphinex induced PCI of gemcitabine to treat bile duct cancer; and preclinical study of Cytotoxic T Lymphocytes for use in the treatment of cancers and other infectious diseases. It is also involved in the preclinical study on the delivery of macromolecules, such as proteins and nucleic acids; vaccine antigens; drugs carried by antibodies; and nanoparticles, as well as some small molecule drugs. The company has a pre-clinical research collaboration agreement with RXi Pharmaceuticals to explore potential synergies. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Lysaker, Norway.

11 Employees
Last Reported Date: 03/24/15
Founded in 2000

pci biotech holding asa (PCIB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 1.6M NOK
Chief Financial Officer
Total Annual Compensation: 916.0K NOK
Compensation as of Fiscal Year 2014.

pci biotech holding asa (PCIB) Key Developments

PCI Biotech Announces Successful Completion of the Third Dose Cohort in the Study for Patients with Inoperable Bile Duct Cancer

PCI Biotech reported that the treatment evaluation of the third dose cohort is completed in the phase I/II study of Amphinex--induced PCI of gemcitabine followed by gecitabine/cisplatin treatment in patients with inoperable bile duct cancer (cholangiocarcinoma). No safety concerns were observed at this dose level. The Cohort Review Committee of clinical experts and company representatives that evaluates the results and provides recommendation for the continuation of the study has recommended that the study progress into the next dose in accordance with the study protocol. Patients for the next dose cohort are currently being screened and will be treated with Amphinex as soon as possible. Bile duct cancer is a rare disease and the company is working actively to increase the patient recruitment rate. The eligible patient population has been expanded to also include metastatic patients and further hospitals in selected European countries are being added to the study.

PCI Biotech Holding ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter Six Months Ended June 30, 2015

PCI Biotech Holding ASA reported unaudited consolidated earnings results for the second quarter six months ended June 30, 2015. For the quarter, the company's operating loss was NOK 6.96 million compared to NOK 8.38 million a year ago. Ordinary loss before taxes was NOK 6.59 million compared to NOK 8.13 million a year ago. Net loss was NOK 6.59 million compared to NOK 8.13 million a year ago, mainly due to increased other income and lower clinical study activities. Cash flow used in operations was NOK 9.34 million compared to NOK 9.25 million a year ago. For the six months, the company's operating loss was NOK 14.67 million compared to NOK 17.79 million a year ago. Ordinary loss before taxes was NOK 14.25 million compared to NOK 17.38 million a year ago. Net loss was NOK 14.25 million compared to NOK 17.38 million a year ago. Net cash flow used in operations was NOK 17.91 million compared to NOK 17.41 million a year ago.

PCI Biotech Holding ASA Provides Update on the ENHANCE Study

PCI Biotech Holding ASA reported that, following a strategic review of the company's assets, it has decided to stop the ENHANCE study and focus the company's resources towards the clinical bile duct cancer study and the promising immunotherapy opportunities offered by the PCI technology. This decision was based on both strategic and clinical considerations. A recent review of the relevant market segment suggests a diminishing opportunity for Amphinex induced treatment with bleomycin in recurrent head and neck cancer, not least due to expected increased competition by emerging immunotherapies for this patient population. In addition, optimizing the light dose for bleomycin-induced tumour ablation by interstitial illumination has turned more complicated than anticipated.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCIB:NO 5.00 NOK 0.00

PCIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PCIB.
View Industry Companies

Industry Analysis


Industry Average

Valuation PCIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PCI BIOTECH HOLDING ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at